Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Elanco Animal Health has received an average rating of "Moderate Buy" from nine research firms, with three hold ratings, five buy ratings, and one strong buy rating.
• The company reported $0.26 earnings per share for the last quarter, exceeding analysts' expectations of $0.20, along with a revenue of $1.24 billion which is a 4.8% increase from the previous year.
• Hedge funds have significantly increased their stake in Elanco, with Allworth Financial LP increasing its holdings by 791.7% during the first quarter.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $17.3333.

Several brokerages have commented on ELAN. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Piper Sandler boosted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, August 11th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Zacks Research downgraded Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Finally, Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a report on Thursday, July 17th.

Elanco Animal Health Price Performance

ELAN stock traded down $0.02 during trading on Friday, hitting $18.47. The company had a trading volume of 12,735,161 shares, compared to its average volume of 7,346,787. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average of $15.45 and a 200 day moving average of $12.64. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $18.87. The firm has a market capitalization of $9.18 billion, a price-to-earnings ratio of 21.48, a P/E/G ratio of 3.43 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same period in the previous year, the business earned $0.30 earnings per share. Elanco Animal Health's revenue for the quarter was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the business. Allworth Financial LP increased its holdings in shares of Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the period. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at about $29,000. NBC Securities Inc. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at about $40,000. Parallel Advisors LLC increased its holdings in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.